<figure><div><img src="https://imgproxy.divecdn.com/4IO9ulge0H6fJ4YiPCWAw7RrHL4AZwLV1lJAWxwEpCk/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTUwMDMyNDE2LmpwZw==.webp" /></div></figure><p>Ahead of a reported White House deal meant to lower the cost of obesity drugs like Wegovy, Novo said “intensifying competition and pricing pressure” led it to lower its yearly sales projections.</p>
Novo narrows sales outlook as GLP-1 price cuts loom
BioPharma Dive Oncology | | Kristin Jensen
Topics: cervical-cancer